{"id":4990,"date":"2026-10-26T08:13:32","date_gmt":"2026-10-26T04:13:32","guid":{"rendered":"https:\/\/silkaesthetic.ge\/?p=4990"},"modified":"2026-10-26T15:52:24","modified_gmt":"2026-10-26T11:52:24","slug":"laser-1550-1927","status":"publish","type":"post","link":"https:\/\/silkaesthetic.ge\/en\/laser-1550-1927\/","title":{"rendered":"What do 1550 and 1927 nm fractional lasers mean?"},"content":{"rendered":"

<\/p>\n

\n
\n\"Conceptual
A general 1550\/1927 nm wavelength schematic; wavelength alone does not establish fractional delivery or an ablative\/nonablative mode.<\/figcaption><\/figure>\n

Sources reviewed: 25 October 2026.<\/p>\n

Reading time: 2 min.<\/p>\n

What do the two numbers tell us?<\/h2>\n

1550 and 1927 nm are wavelengths, not outcome ratings. A historical FDA document for Fraxel re:store Dual describes two laser sources and the distribution of thermal effects in tissue. Its specific indications do not automatically extend to another model or every current instruction for use.<\/p>\n

Source: FDA K101490: Fraxel re:store Dual<\/a><\/p>\n

What does fractional delivery mean?<\/h2>\n

The original fractional-photothermolysis study treated separated microscopic zones of skin. This distribution is an important principle. \u201cFractional\u201d does not mean every laser produces the same effect; nonablative systems in this family should not be equated with CO\u2082 ablation channels.<\/p>\n

Source: Fractional photothermolysis: original concept study<\/a><\/p>\n

How broadly do study findings apply?<\/h2>\n

A study of 20 participants compared a 1927 nm fractional thulium approach with picosecond alexandrite for photopigmentation and signs of ageing. Both groups improved, with some assessments favouring the picosecond group. A small sample and differing treatment schedules cannot establish a universal ranking.<\/p>\n

Source: 755nm picosecond versus 1927nm fractional thulium: randomized study<\/a><\/p>\n

What matters for safety?<\/h2>\n

Skin-resurfacing procedures may cause infection, pigment changes or scarring. Discuss possible reactions and their management beforehand. \u201cNonablative\u201d does not mean risk-free; the exact device and individual skin characteristics still matter.<\/p>\n

Source: ASPS: Skin rejuvenation and resurfacing safety<\/a><\/p>\n

What should we ask at consultation?<\/h2>\n

Ask which wavelength will be used and why. Two sources in a device do not automatically make both necessary. Relate questions to your main goal: what change is expected, how will it be measured and what alternatives exist? Offering another device under a familiar system\u2019s name requires clarification of the actual model and documentation.<\/p>\n